Jump to content

Search the Community

Showing results for tags 'parp inhibitor'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • COMMUNITY
    • Announcements, meetings and other resources
  • ADVANCED PROSTATE CANCER FORUMS
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
  • MEMBER'S STORIES AND NEEDS
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Found 2 results

  1. Jim Marshall (not a doctor) said ... In this video Prostate Cancer Research Institute Executive Director Mark Scholz talks about a clinical trial for men who are metastatic and have rising psa on hormone therapy. The trial is testing whether adding the PARP inhibitor Lynparza (olaparib) to the super-hormone Zytiga (abiraterone) increases its effectiveness. You can find out about the clinical trial at: https://clinicaltrials.gov/ct2/show/study/NCT03732820?show_locs=Y#locn Details there include: inclusion details (things you need to get into the trial); exclusion details (what will keep you out of the trial); and locations. Australian locations include: Box Hill, Australia, 3128 Darlinghurst, Australia, 2010 Greenslopes, Australia, 4120 Herston, Australia, 4029 Kingswood, Australia, 2747 Kurralta Park, Australia, 5037 St Albans, Australia, 3021 Waratah, Australia, 2298 As always, ask your doctor if you think this might be for you. ... end Jim
  2. Hi guys Is anyone enrolled in the Profound trial or have any knowledge of this? The official purpose of the trial is: The purpose of this study is to evaluate the efficacy and safety of olaparib versus enzalutamide or abiraterone acetate in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have homologous recombination repair gene mutations This trial has been enrolling in Australia over the last 6 months or so. I have germline BRCA2 mutation which has probably caused my mCRPC disease. I have been through my options with enzalutamide and abiraterone and have had Docetaxel. Currently looking at commencing a platinum based chemotherapy treatment using Carboplatin, normally used in Ovarian cancer. Any thoughts/experiences around Profound and/or the BRCA mutation and treatment experiences would be very welcome. Thanks and best wishes to you all Martin
×
×
  • Create New...